Status:
COMPLETED
Botulinum Toxin for the Treatment of Depression
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
Hannover Medical School
Conditions:
Depression
Eligibility:
All Genders
25-65 years
Phase:
PHASE2
Brief Summary
Depression is frequently accompanied by a specific sad facial expression. This expression is in part mediated by the same muscle activity that produces frown lines. Based on the assumption that there ...
Eligibility Criteria
Inclusion
- Mild to moderate depression (Ham-D \>=15)
- Therapy with one antidepressant for at least four weeks
- at least moderate frown line
Exclusion
- Bipolar depression
- Psychiatric comorbidity
- Severe somatic comorbidity
- Pregnancy
- Peculiarities at the injection site
- Psychiatric medication other than one antidepressant
- Specific psychotherapy
- Previous application of botulinum toxin
- Medication interfering with botulinum toxin
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00934687
Start Date
August 1 2009
End Date
October 1 2010
Last Update
August 14 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical School Hannover, Psychiatry, Social Psychiatry and Psychotherapy
Hanover, Germany, 30625
2
Psychiatry Hospital of the University of Basel, Basel, Switzerland
Basel, Basel Town, Switzerland